SEC Comment Letter for Viking Therapeutics, Inc. (VKTX) (CIK 0001607678) (VKTX) — Oct 24, 2017
Viking Therapeutics, Inc. (VKTX) (CIK 0001607678)
Date: Oct. 24, 2017 · CIK: 0001607678 · Accession: 0000000000-17-037629
AI Filing Summary & Sentiment
Letter
October 24, 2017 Brian Lian, Ph.D. Chief Executive Officer Viking Therapeutics, Inc. 12340 El Camino Real, Suite 250 San Diego, CA 92130 Viking Therapeutics, Inc. Registration Statement on Form S-1 Filed October 17, 2017 File No. 333-220992Re: Dear Mr. Lian: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Ada D. Sarmento at (202) 551-3798 with any questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Jeff Hartlin, Esq.
Show Raw Text
October 24, 2017
Brian Lian, Ph.D.
Chief Executive Officer
Viking Therapeutics, Inc.
12340 El Camino Real, Suite 250
San Diego, CA 92130
Viking Therapeutics, Inc.
Registration Statement on Form S-1
Filed October 17, 2017
File No. 333-220992Re:
Dear Mr. Lian:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Ada D. Sarmento at (202) 551-3798 with any questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Jeff Hartlin, Esq.